about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Can a 're­dis­cov­ered' drug from In­dia make it big in US im­munol­o­gy space? Dan Brad­bury and his team at Equi­l­li­um want ...

7 years ago
Financing

CStone braves the HKEX with late-stage plans brew­ing for new­ly beefed up I/O pipeline

7 years ago
Financing
China

Or­biMed leads $70M raise for Har­poon Ther­a­peu­tics; Zio­pharm inks com­bo deal with Re­gen­eron's PD-1

7 years ago
News Briefing

Boehringer backs $33M can­cer vac­cine play at Switzer­land's AMAL Ther­a­peu­tics

7 years ago
Financing

One year in, Joanne Kotz as­sumes CEO role at Jnana; Pres­i­dent/Ex­ec­u­tive chair duo will now run Black­Thorn

7 years ago
Peer Review

Bil­lion­aire gifts Har­vard a his­toric $200M to 'ex­pe­dite' trans­la­tion­al bio­med­ical re­search work

7 years ago
People
Discovery

Ab­b­Vie hatch­es plans for a ma­jor new R&D hub close to its part­ners in Bay Area's buzzy Oys­ter Point

7 years ago
R&D
Pharma

Bris­tol-My­ers lays off the last 63 staffers at Zy­mo­Ge­net­ics, shut­ters Seat­tle op­er­a­tions

7 years ago
Pharma

Dana-Far­ber team iden­ti­fies new 'gene traf­fic con­trol' tar­gets in two rare, ag­gres­sive can­cers

7 years ago
Discovery

Cen­trex­ion eyes $70M-$80M in IPO with big plans for PhI­II non-opi­oid painkiller

7 years ago
Financing

Bar­gain sale con­tin­ues: As­traZeneca of­floads three res­pi­ra­to­ry drugs to Co­vis in $350M deal

7 years ago
Pharma

Need al­ter­na­tive fund­ing chan­nels? Per­cep­tive Ad­vi­sors now has $675M de­vot­ed to those deals

7 years ago
Pharma

In an­oth­er try at lung can­cer niche, J&J nabs a po­ten­tial Tagris­so ri­val for $50M-plus

7 years ago
R&D
Pharma

Ky­owa Hakko Kirin gears up to test IDO/PD-1 com­bo; Ab­b­Vie fights Hu­mi­ra biosim­i­lars with 80% price cut in Eu­rope

7 years ago
News Briefing

J&J dumps PhII-ready CD28 au­toim­mune as­set, re­turns rights to French part­ner

7 years ago
Pharma

Sun Bio­Phar­ma founder Michael Cullen steps up; Se­maThera set­tles on per­ma­nent CEO; On­coSec nabs Kel­lie Mal­loy Fo­ert­er ...

7 years ago
Peer Review

Tun­ing in: In­ten­si­ty's im­mune-based chemo de­liv­ery tech at­tracts back­ing of British bil­lion­aire Jim Mel­lon

7 years ago
Financing
Startups

Weeks af­ter launch­ing Aeter­na Zen­taris castoff, Strong­bridge turns around and sells rights to No­vo Nordisk — at a ...

7 years ago
Pharma

Gilead throws its weight — and $50M cash — be­hind Tan­go's I/O dis­cov­ery en­gine

7 years ago
Discovery

Fi­nal­ly! In­novent hikes on Hong Kong de­but amid cloudy mar­ket sen­ti­ments

7 years ago
Financing
China

Roche adds $25M to Halozyme pact for fresh tar­gets; FDA OKs car­dio in­di­ca­tion for J&J's In­vokana

7 years ago
News Briefing

WuXi dives in­to com­pu­ta­tion­al drug dis­cov­ery, launch­es New York-based JV with Schrödinger

7 years ago
Financing
China

No­var­tis has scrapped a fifth of its pro­grams in pur­suit of 'tru­ly im­pact­ful' drugs, Brad­ner re­veals

7 years ago
R&D

Out to chal­lenge Gilead­'s dai­ly pills, Vi­iv scores three-year da­ta on month­ly com­bo; Rigel bags $33M from Asia ...

7 years ago
News Briefing
First page Previous page 108109110111112113114 Next page Last page
A service from the Financial Times